Clinical Outcomes and Toxicity Profile of Cetuximab-Containing Regimen in Locoregionally Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Institution Retrospective Audit

Abstract

Introduction

Recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) remains one of the most prevalent and challenging malignancies worldwide. The combination of cetuximab and chemotherapy continues to be a preferred therapeutic option for these patients. However, despite extensive research aimed at optimizing this combination, the median overall survival (OS) remains limited to approximately 1 year. Long-term survival outcomes continue to be dismal, highlighting the urgent need for more effective treatment strategies and real-world data to guide clinical decision-making.

Objectives

The aim of this study is to evaluate the differential effectiveness of cetuximab-containing treatment in locoregional recurrence versus distant metastasis and identify clinical factors associated with improved survival in patients with R/M SCCHN.

Materials and Methods

This retrospective study included patients with histopathologically confirmed R/M SCCHN, staged according to the Union for International Cancer Control TNM classification and American Joint Committee on Cancer seventh edition. Eligible patients were ≥18 years old, had locoregional recurrence or distant metastasis, an ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2, and no contraindications to treatment. All patients received cetuximab-based treatment during the defined study period. Study endpoints included OS, progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR). Response was assessed using RECIST 1.1 criteria after at least three cycles or earlier if clinically indicated. Safety was evaluated based on CTCAE v5.0 criteria.

Results

A total of 100 patients (median age: 56.5 years) with R/M SCCHN received cetuximab-based chemotherapy. In the overall population, the median OS was 19 months (95% confidence interval [CI]: 17.1–20.9), with 1- and 2-year OS rates of 77.9 and 33%, respectively. Median PFS was 3 months (95% CI: 2.7–3.3), with 3- and 6-month PFS rates of 34.7 and 12.6%, respectively, and tumor responses indicated meaningful disease control (ORR: 37%; DCR: 55%). Patients with locoregional recurrence had significantly longer OS than those with distant metastasis (23 vs. 17 months, p = 0.01). Treatment was well-tolerated.

Conclusion

Cetuximab-based therapy is more effective in achieving disease control and survival in patients with SCCHN who have locoregional recurrence, compared with those with distant metastases.

Keywords

advanced SCCHN - cetuximab-based treatment - distant metastasis - recurrent disease - survival outcomes - toxicity profile

Patient Consent

This study was retrospective in nature and used anonymized data derived from de-identified patient records. Therefore, patient consent was not required.

Publikationsverlauf

Artikel online veröffentlicht:
26. August 2025

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Published 2024. Accessed June 24, 2025 at: https://gco.iarc.who.int/today
• 3 Muzaffar J, Bari S, Kirtane K, Chung CH. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers (Basel) 2021; 13 (02) 338
• 4 Bernier J, Domenge C, Ozsahin M. et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19) 1945-1952
• 5 Rades D, Seidl D, Wollenberg B, Schild SE, Hakim SG. Radiochemotherapy with paclitaxel for recurrent previously irradiated squamous cell carcinoma of the head and neck. Anticancer Res 2016; 36 (10) 5463-5468
• 6 Cooper JS, Zhang Q, Pajak TF. et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012; 84 (05) 1198-1205
• 7 Forastiere AA, Zhang Q, Weber RS. et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31 (07) 845-852
• 8 Price KAR, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012; 13 (01) 35-46
• 9 Samra B, Tam E, Baseri B, Shapira I. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives. J Investig Med 2018; 66 (07) 1023-1030
• 10 Vermorken JB, Mesia R, Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359 (11) 1116-1127
• 11 Guigay J, Aupérin A, Fayette J. et al; GORTEC, AIO, TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2021; 22 (04) 463-475
• 12 Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101 (10) 2222-2229
• 13 Mirabile A, Miceli R, Calderone RG. et al. Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck 2019; 41 (06) 1895-1902
• 14 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
• 15 National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. Published 2017. Accessed June 24, 2025 at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5 X7.pdf
• 16 Burtness B, Harrington KJ, Greil R. et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394 (10212): 1915-1928
• 17 Tourneau CL, Ghiani M, Cau MC. et al. Cetuximab + platinum-based therapy (PBT) as a first- line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): an observational study (ENCORE). Ann Oncol 2018; 29: viii377
• 18 Keam B, Machiels JP, Kim HR. et al. Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open 2021; 6 (06) 100309
• 19 Erbitux | European Medicines Agency (EMA). July 14, 2009. Accessed April 15, 2025 at; https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux
• 20 Guo Y, Luo Y, Zhang Q. et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: efficacy and safety results of the randomised, phase III CHANGE-2 trial. Eur J Cancer 2021; 156 (156) 35-45
• 21 Yokota T, Ota Y, Fujii H. et al. Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). Int J Clin Oncol 2021; 26 (02) 316-325